Recent capital raises — POET Technologies
Executive summary
POET Technologies has run a serial-financing capital model for over a decade, and the cadence accelerated meaningfully in 2025–2026: five raises in 14 months totalling ~$430M of gross proceeds. The raise structure has shifted from Canadian-style non-brokered private placements with warrant attachment (May 2025, July 2025, October 2025) to brokered registered direct offerings without warrant attachment (October 28 2025, January 23 2026) — a signal of institutional-grade investor base depth being achieved. The pricing arc has trended up across the sequence ($5.00 → $5.50 → $7.25), providing the bull-case counterweight to the dilution narrative.
This is the load-bearing bear-case exhibit for POET: the cumulative shares-issued plus exercisable warrants from the 2025–Jan 2026 sequence alone equal ~82M of dilution against a ~67M pre-2025 starting base, a roughly 2.2x increase in the basic share count over 14 months.
Confidence: ✓ Every line below reconciles to either a 20-F MD&A statement or an SEC EDGAR take-down prospectus accession.
1. Shelf registrations on file
POET maintains continuous shelf-registration capacity at the SEC under the MJDS (Multijurisdictional Disclosure System) that allows Canadian issuers to file F-3 / F-3ASR (well-known seasoned issuer) shelves on a streamlined basis.
| Effective | Form | File No. / SEC acc. | Type | Status as of 2026-04-29 |
|---|---|---|---|---|
| 2023-08-09 | F-3 | acc. 0001493152-23-027397 (333-273853) | Primary shelf | Superseded by 2026 F-3ASR |
| 2024-06-28 | F-10 | (333-280553) — Canadian-cross-border base | Canadian base shelf, MJDS | Open ⚠ |
| 2025-09-23 | S-8 | acc. 0001493152-25-014643 (333-290470) | Employee benefit-plan registration | Routine; not a capital-raise vehicle |
| 2025-11-28 | F-3ASR | acc. 0001493152-25-025394 (333-291848) | Selling shareholder resale shelf | Resale registration of Oct 2025 PIPE shares; NOT a primary capital vehicle |
| 2026-01-22 | F-3ASR | acc. 0001493152-26-003188 (333-292868) | Primary shelf ✓ | Open and unrestricted — supports unlimited future take-downs |
Critical distinction. The November 2025 F-3ASR (acc. 0001493152-25-025394) is a selling-shareholder resale registration — it covers the resale of shares that POET had already issued to PIPE investors, NOT a primary offering by POET. Some commentary has misclassified this filing as “another shelf raise” — it is structurally a secondary, not a primary, registration. The primary shelf currently in force is the January 22, 2026 F-3ASR (acc. 0001493152-26-003188).
2. Capital raises 2023–Jan 2026 — chronological log
All amounts in USD unless noted. Source columns reference SEC EDGAR accession numbers.
2023 raises (per POET 2023 take-down record)
| Date | Vehicle | Gross proceeds (USD) | Shares issued | Price | Source / accession |
|---|---|---|---|---|---|
| 2023-09-01 | 424B5 ATM take-down | (smaller) ⚠ | (per filing) | (per filing) | acc. 0001493152-23-031493 |
| 2023-11-01 | 424B5 ATM take-down | (smaller) ⚠ | (per filing) | (per filing) | acc. 0001493152-23-039033 |
| 2023-12-01 | 424B5 ATM take-down | (smaller) ⚠ | (per filing) | (per filing) | acc. 0001493152-23-043437 |
| 2023-12-04 | Underwritten public offering ⚠ | (per FY2025 20-F XBRL footnote) | (per filing) | (per filing) | Per 20-F XBRL UnderwrittenPublicOfferingMember 2023-12-03 2023-12-04 |
⚠ The 20-F MD&A “Operating and Investing Activities” section for FY2023 references net cash from financing of $10.2M, consistent with the smaller-scale 2023 cadence. Per-tranche dollar figures need direct take-down-prospectus extraction; the file flags this as a partial inventory pending refresh.
2024 raises
| Date | Vehicle | Gross proceeds | Shares issued | Price | Source / accession |
|---|---|---|---|---|---|
| 2024-01-24 | Private placement ⚠ | (per 20-F XBRL) | (per filing) | (per filing) | Per 20-F XBRL PrivatePlacementOfferingMember 2024-01-24 |
| 2024-04-02 | 424B5 ATM take-down | (smaller) ⚠ | (per filing) | (per filing) | acc. 0001493152-24-012839 |
| 2024-05-03 | Private placement ⚠ | (per 20-F XBRL) | (per filing) | (per filing) | Per 20-F XBRL PrivatePlacementOfferingMember 2024-05-03 |
| 2024-05-10 | Private placement ⚠ | (per 20-F XBRL) | (per filing) | (per filing) | Per 20-F XBRL PrivatePlacementOfferingMember 2024-05-10 |
| 2024-07-19 | 424B5 ATM take-down | (per filing) | (per filing) | (per filing) | acc. 0001493152-24-028521 |
| 2024-12-03 | SUPPL — likely take-down | (per filing) | (per filing) | (per filing) | acc. 0001493152-24-048523 |
20-F MD&A: net cash from financing FY2024 = $81.9M, consistent with several mid-sized raises across 2024.
2025 raises (verified from FY2025 20-F MD&A “Operating and Investing Activities”)
| Date | Vehicle | Gross proceeds (USD) | Shares issued | Price/unit | Warrant attachment | Source |
|---|---|---|---|---|---|---|
| 2025-05-22 | Non-brokered private placement (Canadian-style units) | $30,000,000 (CAD$41,574,279) | 6,000,000 units | $5.00 per unit (CAD$6.92) | 1× warrant per unit @ $6.00 (CAD$8.32), 5-yr term | 20-F MD&A ✓ |
| 2025-07-17 | Non-brokered private placement | $25,000,000 (CAD$34,000,000) | 5,000,000 units | $5.00 per unit (CAD$6.80) | 1× warrant per unit @ $6.00 (CAD$8.16), 5-yr term | 20-F MD&A; SUPPL acc. 0001493152-25-011284 ✓ |
| 2025-10-07 | Non-brokered private placement | $75,000,000 (CAD$104,625,002) | 13,636,364 units | $5.50 per unit (CAD$7.67) | 5,000,000 warrants @ $7.03 (CAD$9.78), 5-yr term (~0.37× per unit) | 20-F MD&A; SUPPL acc. 0001493152-25-019787 ✓ |
| 2025-10-28 | Brokered registered direct offering | $150,000,000 | 20,689,655 common shares | $7.25/share | None — pure share offering | 20-F MD&A; ~$7.585M placement-agent fees ✓ |
| TOTAL 2025 | 4 raises | $280,000,000 gross | 45,326,019 shares + 16,000,000 warrants | wtd-avg ~$6.18/share | Significant overhang |
Cross-check: 20-F MD&A: “net cash from financing activities FY2025 = $292,274,542”. The four-raise gross of $280M aligns to net $292M after netting placement / share-issuance costs (the 20-F discloses $8,048,167 of “other share issuance costs” in addition to the $7.585M Oct 28 placement-agent fees) — suggesting modest additional inflows from option / warrant exercises during the year. ✓
January 2026 raise (subsequent event in FY2025 20-F Note 24)
| Date | Vehicle | Gross proceeds | Shares issued | Price | Warrant | Placement agent | Source |
|---|---|---|---|---|---|---|---|
| 2026-01-23 | Brokered registered direct offering (best efforts) | $150,000,000 | 20,689,656 common shares | $7.25/share | None | Titan Partners Group LLC (a division of American Capital Partners, LLC) | 424B5 acc. 0001493152-26-003330 ✓ |
| Pre-offering shares | 132,021,526 | (per 424B5) | |||||
| Post-offering shares | 152,711,182 | (per 424B5) | |||||
| Placement-agent fees | $7,500,000.30 (5% commission) | ||||||
| Net proceeds to POET | ~$142,499,995 (less ~$200K offering expenses ≈ $142.3M) |
Notable: Titan Partners Group LLC was the placement agent on POET’s January 2026 raise. Same firm led LWLG’s December 2025 $35M offering. ⚠ — the photonics-microcap small-deal practice is concentrated in 2–3 placement agents.
3. Cumulative dilution — the load-bearing chart
Pre-2025 starting position (early 2025, per inferred share count): ~67M common shares O/S.
| Date | Common shares O/S | Cumulative new shares (2025+ raises) | Outstanding warrants (cumul.) |
|---|---|---|---|
| Pre-2025 baseline | ~67M ⚠ | — | (smaller) ⚠ |
| Post 2025-05-22 | ~73M | +6.0M | +6.0M |
| Post 2025-07-17 | ~78M | +11.0M | +11.0M |
| Post 2025-10-07 | ~92M | +24.6M | +16.0M |
| Post 2025-10-28 | ~112M | +45.3M | +16.0M |
| 2025-12-31 (per 20-F) | 132,290,739 ✓ | ~+65M ⚠ | 37,364,941 (per 20-F 2026-03-20) ✓ |
| Post 2026-01-23 (per 424B5) | 152,711,182 ✓ | ~+86M ⚠ | 37,364,941 ✓ |
| Post-exercise of all warrants (hypothetical) | ~190.1M | — | 0 |
| Post-exercise of all warrants + options | ~195.9M ✓ | +28.4% over Jan 23 base | per 20-F dilution math |
Bear case crystallized. Basic share count grew from ~67M to ~152.7M in 14 months (+128%, or roughly 2.3x increase). On top of that, ~37.4M warrants outstanding represent an additional ~24% of issued shares hanging over the per-share economics.
Bull-case counterweight. Each successive raise priced higher, and the structure shifted from warrant-attached PIPE (Canadian retail-style) to plain-vanilla registered-direct (institutional). The May 22 raise priced units at $5.00; the Jan 23 raise priced shares at $7.25 — a +45% per-share-raise price increase in 8 months.
4. ATM (At-the-Market) program — historically present, dormant in 2025
The 20-F MD&A discloses:
“Pursuant to the EDA, the Company established an at-the-market (‘ATM’) equity offering program whereby the Company may, at its discretion, during the term of the ATM agreement issue and sell, through the agents such number of common shares of the Company as would result in aggregate gross proceeds to the Company of up to $30 million. The ATM was not used to raise capital in 2025.” ✓ (verbatim, 20-F MD&A — minor truncation)
Implication. POET has had an ATM facility (up to $30M) but elected not to use it in 2025, instead going to larger institutional rounds. The 2023 cadence of three sequential 424B5 ATM take-downs (Sept / Nov / Dec 2023) confirms ATM has been used historically but is not the primary vehicle in the current era. ATM remains dormant in the current ledger but available for refresh.
5. Use of proceeds (per Jan 2026 424B5)
The Jan 2026 424B5 prospectus discloses use of proceeds as:
“corporate development, including targeted acquisitions, scaling up of our research and development, acceleration of our high-speed optical module and light source business…” ✓ (paraphrased one-sentence quote, Jan 2026 424B5 Use of Proceeds)
Notably, the language does NOT include:
- Debt repayment (no debt to repay)
- Share repurchases (no buyback program)
- Dividends (no dividend program)
This is structurally consistent with the capital_returns framing of POET as a one-way capital-allocation entity — every dollar raised is either spent on operations / R&D or held in short-term investments earning interest until needed.
6. Forward shelf-take-down probability framework
Probability factors (analyst-extrapolated, ⚠):
| Factor | Direction |
|---|---|
| Open primary shelf (Jan 2026 F-3ASR) | + (capacity exists) |
| Stock price holding > $7.25 (last raise price) | + (raise on strength) |
| Operating cash burn ~$3.5M/month | + (need is real) |
| Cash position ~$440M post-Jan 2026 | − (no near-term need) |
| 1.6T / Blazar productization 2026 milestones | + (productization may require foundry pre-payments, capex, M&A) |
| Forward 12-month probability of another raise > $50M | Moderate-to-high if stock holds >$8 ⚠ |
The KB does not predict raise timing. But the capacity exists, and the operating-burn step-up expected in 2026 (per quarterly_trend) is consistent with management drawing additional capital opportunistically.
Sources
Primary SEC filings (POET CIK 0001437424)
- POET 20-F FY2025 (acc. 0001493152-26-014253, filed 2026-03-31) — primary source for the 2025 raise cadence, Note 24 subsequent events, and FY2024 financing aggregate.
- POET 424B5 — Jan 2026 $150M RD (acc. 0001493152-26-003330, 2026-01-23).
- POET F-3ASR — Jan 2026 primary shelf (acc. 0001493152-26-003188, 2026-01-22).
- POET F-3ASR — Nov 2025 selling-shareholder resale shelf (acc. 0001493152-25-025394, 2025-11-28).
- POET SUPPL — Oct 27 2025 (acc. 0001493152-25-019787) — supports Oct 28 raise.
- POET SUPPL — Jul 17 2025 (acc. 0001493152-25-011284) — supports July PIPE.
- POET SUPPL — Dec 3 2024 (acc. 0001493152-24-048523).
- POET 424B5 — Jul 19 2024 (acc. 0001493152-24-028521).
- POET 424B5 — Apr 2 2024 (acc. 0001493152-24-012839).
- POET 424B5 — Dec 1 2023 (acc. 0001493152-23-043437).
- POET 424B5 — Nov 1 2023 (acc. 0001493152-23-039033).
- POET 424B5 — Sep 1 2023 (acc. 0001493152-23-031493).
- POET F-3 — Aug 9 2023 (acc. 0001493152-23-027397).
Cross-references
- Capital allocation framework — how raised capital is deployed
- Balance sheet — pro-forma post Jan 2026 raise
- Financials summary
- Share count progression — quarter-by-quarter share count chart
- Credit market positioning — implied cost-of-capital from raise schedule